Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients (NCT07042321) | Clinical Trial Compass
RecruitingNot Applicable
Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients
China300 participantsStarted 2024-06-01
Plain-language summary
The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are:
* How does the TyG index correlate with the early detection of MVO?
* What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥ 18 years.
* STEMI symptom onset time \< 12 hours.
* STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias.
* Very high-risk NSTEMI; undergoing emergency PCI treatment.
* Voluntary signed informed consent form.
Exclusion Criteria:
* Non-obstructive acute myocardial infarction.
* Severe chronic kidney disease (defined as estimated glomerular filtration rate \<20 mL/min per 1.73 m²).
* Pregnant women or those planning to become pregnant.
* Failure of emergency PCI.
* Unclear CMR images
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The presence or absence of microvascular obstruction (MVO) diagnosed by cardiac magnetic resonance (CMR) within 3-7 days postoperatively
Timeframe: 3-7 days postoperatively
Trial details
NCT IDNCT07042321
SponsorThe Third Xiangya Hospital of Central South University